510(k) device
Mendit
Escala Medical, Ltd. · Fixation, Non-Absorbable Or Absorbable, For Pelvic Use (PBQ, Class II) · First FDA decision Mar 4, 2026, newest Mar 4, 2026Pelvic organ prolapse
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Mendit"
MAUDE reports
0
Brand "Mendit", since 2015
PubMed studies
6
Mentioning "Mendit"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Mendit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Mendit510(k)
K260380 · Decided Mar 4, 2026 · 27 days after receipt
Device type: Fixation, Non-Absorbable Or Absorbable, For Pelvic Use (PBQ) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Mendit", any status and sponsor, newest update first.
No registered device study names "Mendit".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Mendit", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PBQ
65 reports: 48 malfunction, 16 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Mendit"[tiab]. The summary above synthesizes these.
- Phylogenetic and genetic variation of common mudskippers (Periophthalmus kalolo Lesson, 1831) from the southern coast of Java, Indonesia inferred from the COI mitochondrial gene.
Arisuryanti T, Waskito Aji K, Nur Shabrina F, et al. · J Genet Eng Biotechnol · 2024
- An international comparison of the deinstitutionalisation of mental health care: Development and findings of the Mental Health Services Deinstitutionalisation Measure (MENDit).
Taylor Salisbury T, Killaspy H, King M · BMC Psychiatry · 2016Research Support, Non-U.S. Gov't
- Short-Term Safety and Operative Outcomes of Sacrospinous Ligament Fixation Using the Mendit Device.
Hadizadeh A, Chill HH, Leffelman A, et al. · J Minim Invasive Gynecol · 2026
- Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K, Schaap DP, Voogt ELK, et al. · BMC Cancer · 2022Clinical Trial Protocol
- Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT Trial.
Banken E, van den Berg K, van Hellemond IEG, et al. · Int J Radiat Oncol Biol Phys · 2026Multicenter Study, Clinical Trial, Phase II
- A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trial.
Banken E, Borg M, van Hellemond IEG, et al. · BMC Cancer · 2026Clinical Trial Protocol
Other devices of this type
Also filed under product code PBQ.
- ApyxEscala Medical · 510(k) 2023
- Saffron Fixation SystemColoplast A/S · 510(k) 2022
- NeuGuidePop Medical Solutions · 510(k) 2016
- Endofast Reliant Scp, Endofast Reliant LapIbi Israel Biomedical Innovations , Ltd. · 510(k) 2013
- AnchorsureNeomedic International S.L. · 510(k) 2012
- Gynecare Prolene Fastener SystemETHICON, Inc. · 510(k) 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.